Privately-held Transposagen Biopharmaceuticals and Janssen Biotech have entered into a research collaboration and licensing agreement for development of allogeneic Chimeric Antigen Receptor T-cells (CAR-T).
Johnson & Johnson’s Janssen will enter into the CAR-T development field with pharma giants including Novartis, Celgene and GlaxoSmithKline (GSK). CAR-T therapies have shown promise in early human clinical trials to date for treating blood cancers, and CAR-Ts have the potential for use without the need of matching donor with recipient.
Under the agreement, Janssen will pay up to $292 million per CAR-T therapeutic, which includes an upfront fee and potential development, regulatory and commercial milestone payments. Transposagen will also receive tiered royalties on net sales of any allogeneic CAR-T products that are commercialized by Janssen.
Transposagen will use its proprietary genome editing technologies to create the allogeneic CAR-T therapies. Under the agreement, Janssen has exclusive rights to any allogeneic CAR-T therapy that is jointly developed by the companies. Janssen has also received a non-exclusive research license to use Transposagen’s proprietary gene editing technologies for gene and cell therapy solutions for treating diseases with significant unmet medical need. Transposagen will retain the rights to develop autologous CAR-T therapies and CAR-T therapies using Natural Killer (NK) cells or NK-like cells.
The agreement will last for three years, during which both companies will collaboratively conduct preclinical research on the treatment. Janssen will be responsible for manufacturing and commercialization of allogeneic CAR-T therapies.
“The research collaboration with Janssen will pair Transposagen’s cutting-edge gene editing and gene delivery technology and expertise with Janssen industry-leading technologies in the antibody alternative areas to create what may be the ideal CAR-T therapy,” said Eric Ostertag, President and CEO of Transposagen.
Source: Transposagen Biopharmaceuticals, Inc.
Last updated: 11/26/14; 11:30am EST